Knowledge Gaps Surrounding CRPC Risk Assessment, Treatment

Over the past few years, the treatment options for castration-resistant prostate cancer (CRPC) have increased to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metastasis-targeted agents. Due to an absence of large prospective trials, clinical decision making needs to be based on many different factors, including optimal treatment sequences and combinations, patient health status (eg, asymptomatic or symptomatic), rate of disease progression...
Continue reading

Urology/Oncology Preferences: Continuing Medical Education

In order to accurately recognize the continuing medical education (CME) needs and preferences of urology/oncology health care providers, i3 Health administered a survey to participants at the 66th Society of Government Service Urologists Kimbrough Urological Seminar. The results obtained from the survey will be used by i3 Health in the planning and implementation of CME-approved activities. Of the 22 participants who completed the survey, 72.7% were urologists, 18.2% were residents, 4.5% were fe...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.